Liposomes as delivery systems for antibiotics

International Journal of Pharmaceutics

Volumn 387, Issue 1-2, 2010, Pages 187-198

  Drulis Kawa, Zuzanna ^a   Dorotkiewicz Jach, Agata ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

Antibiotic; Bacteria; Liposomes

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM; CIPROFLOXACIN; DRUG CARRIER; GENTAMICIN; ISONIAZID; LIPOSOME; MEROPENEM; OXACILLIN; POLYMYXIN B; QUINOLONE DERIVATIVE; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ADSORPTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; ENCAPSULATION; ENDOCARDITIS; HYDROPHILICITY; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; SUSTAINED DRUG RELEASE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; LIPOSOMES;

EID: 77649189516     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.11.033     Document Type: Review

References (116)

1. Abeylath S.C., Turos E. Drug delivery approaches to overcome bacterial resistance to beta-lactam antibiotics. Expert Opin. Drug Deliv. 2008, 5931-5949.
2. Alipour M., Halwani M., Omri A., Suntres Z.E. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int. J. Pharm. 2008, 355:293-298.
3. Allen T.M. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998, 56:747-756.
4. Allen T.M., Martin F.J. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. 2004, 31:5-15.
5. Bakker-Woudenberg I.A.J.M. Long-circulating sterically stabilized liposomes as carriers of agents. Int. J. Antimicrob. Agents 2002, 19:299-311.
6. Bakker-Woudenberg I.A.J.M., Lokerse A.F., Vink-van den Berg J.C., Roerdink F.H., Michel M.F. Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages. Antimicrob. Agents Chemother. 1986, 30:295-300.
7. Bakker-Woudenberg I.A.J.M., Lokerse A.F., Roerdink F.H. Antibacterial activity of liposome-entrapped ampicillin in vitro and in vivo in relation to the lipid composition. J. Pharmacol. Exp. Ther. 1989, 251:321-327.
8. Bakker-Woudenberg I.A.J.M., Lokerse A.F., ten Kate M.T., Mouton J.W., Woodle M.C., Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. Eur. J. Clin. Microbiol. Infect. Dis. 1993, 12:S61-S67.
9. Bakker-Woudenberg I.A.J.M., Storm G., Woodle M.C. Liposomes in the treatment of infections. J. Drug Target. 1994, 2:363-371.
10. Bakker-Woudenberg I.A.J.M., ten Kate M.T., Stearne-Cullen L.E., Woodle M.C. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. J. Infect. Dis. 1995, 171:938-947.
11. Bakker-Woudenberg I.A.J.M., ten Kate M.T., Guo L., Working P., Mouton J.W. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob. Agents Chemother. 2001, 45:1487-1492.
12. Bakker-Woudenberg I.A.J.M., ten Kate M.T., Guo L., Working P. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob. Agents Chemother. 2002, 46:2575-2581.
13. Beaulac C., Clement-Major S., Hawari J., Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 1996, 40:665-669.
14. Beaulac C., Clement-Major S., Hawari J., Lagace J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J. Microencapsul. 1997, 14:335-348.
15. Beaulac C., Sachetelli S., Lagace J. In vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J. Antimicrob. Chemother. 1998, 41:35-41.
16. Brandissou S., Hamel B., Veillet B., Kinowski J.M., Yagoubi N., Bressolle F. Mycobacterium avium complex infections: the point on the treatments. Therapie 1997, 52:65-71.
17. Briones E., Colino C.I., Lanao J.M. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J. Control. Release 2008, 125:210-227.
18. Bruinenberg P., Otulana B., Blanchard J., Morishigi R., Cipolla D., Wilson J., Serisier D. The effect of once-a day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization. Pediatr. Pulmonol. 2008, (Suppl 31):344. (abstract #401).
19. Campanha M.T., Mamizuka E.M., Carmona-Ribeiro A.M. Interactions between cationic liposomes and bacteria: the physical-chemistry of the bactericidal action. J. Lipid Res. 1999, 40:1495-1500.
20. Carmona-Ribeiro A.M. Interactions between cationic liposomes and drugs or biomolecules. An. Acad. Bras. Cienc. 2000, 72:39-43.
21. Catuogno C., Jones M.N. The antibacterial properties of solid supported liposomes on Streptococcus oralis biofilms. Int. J. Pharm. 2003, 257:125-140.
22. ® liposomes: from theory to product. Adv. Drug Deliv. Rev. 1997, 24:165-177.
23. Cordeiro C., Wiseman D.J., Lutwyche P., Uh M., Evans J.C., Finlay B.B., Webb M.S. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar Typhimurium intracellular infection model. Antimicrob. Agents Chemother. 2000, 44:533-539.
24. de Steenwinkel J.E., van Vianen W., ten Kate M.T., Verbrugh H.A., van Agtmael M.A. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. J. Antimicrob. Chemother. 2007, 60:1064-1073.
25. Deol P., Khuller G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta 1997, 1334:161-172.
26. DiTizio V., Ferguson G.W., Mittelman M.W., Khoury A.E., Bruce A.W., DiCosmo F. A liposomal hydrogel for the prevention of bacterial adhesion to catheters. Biomaterials 1998, 19:1877-1884.
27. Donald P.R., Frederick A.S., Venter A., Smit E., Parkin D.P., Van de Wal B., Mitchison D.A. The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. J. Antimicrob. Chemother. 2001, 48:877-880.
28. Drulis-Kawa Z., Gubernator J., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. Int. J. Pharm. 2006, 315:59-66.
29. Drulis-Kawa Z., Gubernator J., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. A comparison of the in vitro antimicrobial activity of liposomes containing meropenem and gentamicin. Cell. Mol. Biol. Lett. 2006, 11:360-375.
30. Drulis-Kawa Z., Dorotkiewicz-Jach A., Gubernator J., Gula G., Bocer T., Doroszkiewicz W. The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. Int. J. Pharm. 2009, 367:211-219.
31. Dubus J.C., Ravilly S. Inhaled therapies in cystic fibrosis. Rev. Mal. Respir. 2008, 25:989-998.
32. Dupont L., Minic P., Fustik S., Mazurek H., Solyom E., Feketeova A. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Cyst. Fibros. 2008, 7(Suppl 2):S26. (abstract #102).
33. Dutt M., Khuller G.K. Liposomes and PLG microparticles as sustained release antitubercular drug carriers-an in vitro-in vivo study. Int. J. Antimicrob. Agents 2001, 18:245-252.
34. Duzgunes N., Perumal V., Kesavalu L., Goldstein J.A., Debs R.J., Gangadharam P.R. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-Mycobacterium intracellulare complex infection in beige mice. Antimicrob. Agents Chemother. 1988, 32:1404-1411.
35. Duzgunes N., Ashtekar D.R., Flasher D.L., Ghori N., Debs R.J., Friend D.S., Gangadharam P.R. Treatment of Mycobacterium avium-Mycobacterium intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J. Infect. Dis. 1991, 164:143-151.
36. Duzgunes N., Flasher D., Reddy M.V., Luna-Herrera J., Gangadharam P.R. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin. Antimicrob. Agents Chemother. 1996, 40:2618-2621.
37. Ellbogen M.H., Olsen K.M., Gentry-Nielsen M.J., Preheim L.C. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J. Antimicrob. Chemother. 2003, 51:83-91.
38. Forssen E., Willis M. Ligand-targeted liposomes. Adv. Drug Deliv. Rev. 1998, 29:249-271.
39. Furneri P.M., Fresta M., Puglisi G., Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob. Agents Chemother. 2000, 44:2458-2464.
40. Gerasimov O.V., Boomer J.A., Qualls M.M., Thompson D.H. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv. Drug Deliv. Rev. 1999, 38:317-338.
41. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995, 13:527-537.
42. Gubernator J., Drulis-Kawa Z., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against Gram-negative clinical bacterial strains. Lett. Drug Des. Discov. 2007, 8:297-304.
43. Halwani M., Mugabe C., Azghani A.O., Lafrenie R.M., Kumar A., Omri A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J. Antimicrob. Chemother. 2007, 60:760-769.
44. Halwani M., Blomme S., Suntres Z.E., Alipour M., Azghani A.O., Kumar A., Omri A. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int. J. Pharm. 2008, 358:278-284.
45. Hamidi M., Azadi A., Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006, 13:399-409.
46. Hancock R.E., Brinkman F.S. Function of pseudomonas porins in uptake and efflux. Ann. Rev. Microbiol. 2002, 56:17-38.
47. Hernandez-Borrell J., Montero M.T. Does ciprofloxacin interact with neutral bilayers? An aspect related to its antimicrobial activity. Int. J. Pharm. 2003, 252:149-157.
48. Hernandez-Caselles T., Vera A., Crespo F., Villalain J., Gomez-Fernandez J.C. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin. Am. J. Vet. Res. 1989, 50:1486-1488.
49. Jones M.N., Francis S.E., Hutchinson F.J., Lyle I.G. Targeting and delivery of bactericide to adsorbed oral bacteria by use of proteoliposomes. Biochim. Biophys. Acta 1993, 1147:251-261.
50. Jones M.N., Kaszuba M., Reboiras M.D., Lyle I.G., Hill K.J., Song Y.H., Wilmot S.W., Creeth J.E. The targeting of phospholipid liposomes to bacteria. Biochim. Biophys. Acta 1994, 1196:57-64.
51. Kadurugamuwa J.L., Clarke A.J., Beveridge T.J. Surface action of gentamicin on Pseudomonas aeruginosa. J. Bacteriol. 1993, 175:5798-5805.
52. Kadurugamuwa J.L., Lam J.S., Beveridge T.J. Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect. Antimicrob. Agents Chemother. 1993, 37:715-721.
53. Kaszuba M., Robinson A.M., Song Y.H., Creeth J.E., Jones M.N. The visualisation of the targeting of phospholipids liposomes to bacteria. Colloids Surf. B Biointerfaces 1997, 8:321-332.
54. Kim H.J., Gias E.L.M., Jones M.N. The adsorption of cationic liposomes to Staphylococcus aureus biofilms. Colloids Surf. A Physicochem. Eng. Asp. 1999, 149:561-570.
55. Kotra L.P., Haddad J., Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob. Agents Chemother. 2000, 44:3249-3256.
56. ®). Program and Abstract of the Ninth European Congress of Clinical Microbiology and Infectious Diseases. Clin. Microbiol. Inf., 5S3 1999, 136. (Abstract P194).
57. Kshirsagar N.A., Pandya S.K., Kirodian B.G., Sanath S. Liposomal drug delivery system from laboratory to clinic. J. Postgrad. Med. 2005, 51:S5-S15.
58. Labana S., Pandey R., Sharma S., Khuller G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Agents 2002, 20:301-304.
59. Lasic D.D. Novel applications of liposomes. Trends Biotechnol. 1998, 16:307-321.
60. Li Z., Zhang Y., Wurtz W., Lee J.K., Malinin V.S., Durwas-Krishnan S., Meers P., Perkins W.R. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol. Med. Pulm. Drug Deliv. 2008, 21:245-254.
61. Livermore D.M. Of pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 2001, 47:247-250.
62. Lutwyche P., Cordeiro C., Wiseman D.J., St-Louis M., Uh M., Hope M.J., Webb M.S., Finlay B.B. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob. Agents Chemother. 1998, 42:2511-2520.
63. Marier J.F., Lavigne J., Ducharme M.P. Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection. Antimicrob. Agents Chemother. 2002, 46:3776-3781.
64. Marier J.F., Brazier J.L., Lavigne J., Ducharme M.P. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J. Antimicrob. Chemother. 2003, 52:247-252.
65. Martin N.L., Beveridge T.J. Gentamicin interaction with Pseudomonas aeruginosa cell envelope. Antimicrob. Agents Chemother. 1986, 29:1079-1087.
66. Maruyama K., Takizawa T., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Adv. Drug Deliv. Rev. 1997, 24:235-242.
67. Montero M.T., Saiz D., Sitges R., Vazquez J.L., Hernandez-Borrell J. Influence of physicochemical properties of fluoroquinolones on encapsulation efficiency in liposomes. Int. J. Pharm. 1996, 138:113-120.
68. Mouritsen O.G., Jorgensen K. A new look at lipid-membrane structure in relation to drug research. Pharm. Res. 1998, 15:1507-1519.
69. Mugabe C., Halwani M., Azghani A.O., Lafrenie R.M., Omri A. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50:2016-2022.
70. Nightingale S.D., Saletan S.L., Swenson C.E., Lawrence A.J., Watson D.A., Pilkiewicz F.G., Silverman E.G., Cal S.X. Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrob. Agents Chemother. 1993, 37:1869-1872.
71. Oh Y.K., Nix D.E., Straubinger R.M. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob. Agents Chemother. 1995, 39:2104-2111.
72. Okusanya O.O., Bhavnani S.M., Hammel J., Minic P., Dupont L.J., Forrest A., Mulder G.J., Mackinson C., Ambrose P.G., Gupta R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 2009, (Epub ahead of print).
73. Omri A., Ravaoarinoro M. Comparison of the bactericidal action of amikacin, netilmicin and tobramycin in free and liposomal formulation against Pseudomonas aeruginosa. Chemotherapy 1996, 42:170-176.
74. Omri A., Ravaoarinoro M. Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria. Int. J. Antimicrob. Agents 1996, 7:9-14.
75. Omri A., Suntres Z.E., Shek P.N. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 2002, 64:1407-1413.
76. Peyman G.A., Charles H.C., Liu K.R., Khoobehi B., Niesman M. Intravitreal liposome-encapsulated drugs: a preliminary human report. Int. Ophthalmol. 1988, 12:175-182.
77. Piddock L.J. Antibacterials-mechanisms of action. Curr. Opin. Microbiol. 1998, 1:502-508.
78. Pinto-Alphandary H., Andremont A., Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 2000, 13:155-168.
79. Poole K. Multidrug resistance in Gram-negative bacteria. Curr. Opin. Microbiol. 2001, 4:500-508.
80. Poole K. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. Curr Pharm Biotechnol. 2002, 3:77-98.
81. Rivera M., Bryan L.E., Hancock R.E., McGroarty E.J. Heterogeneity of lipopolysaccharides from Pseudomonas aeruginosa: analysis of lipopolysaccharide chain length. J. Bacteriol. 1988, 170:512-521.
82. Robinson A.M., Creeth J.E., Jones M.N. The specificity and affinity of immunoliposome targeting to oral bacteria. Biochim. Biophys. Acta 1998, 1369:278-286.
83. Robinson A.M., Bannister M., Creeth J.E. The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide. Colloids Surf. A Physicochem. Eng. Asp. 2001, 186:43-53.
84. Rukholm G., Mugabe C., Azghani A.O., Omri A. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int. J. Antimicrob. Agents 2006, 27:247-252.
85. Sachetelli S., Beaulac C., Rijon R., Lagace J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal tobramycin formulation for the treatment of chronic infections in lungs. Biochim. Biophys. Acta 1999, 1428:334-340.
86. Sachetelli S., Khalil H., Chen T., Beaulac C., Sénéchal S., Lagace J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim. Biophys. Acta 2000, 1463:254-266.
87. Salem I.I., Duzgunes N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int. J. Pharm. 2003, 250:403-414.
88. Sanderson N.M., Jones M.N. Encapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidis. J. Drug Target 1996, 4:181-189.
89. Sanderson N.M., Guo B., Jacob A.E., Handley P.S., Cunniffe J.G., Jones M.N. The interaction of cationic liposomes with the skin-associated bacterium Staphylococcus epidermidis: effects of ionic strength and temperature. Biochim. Biophys. Acta 1996, 1283:207-214.
90. Sapra P., Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 2003, 42:439-462.
91. Scherphof G.L., Velinova M., Kamps J., Donga J., van der Want H., Kuipers F., Havekes L., Daemen T. Modulation of pharmacokinetic behavior of liposomes. Adv. Drug Deliv. Rev. 1997, 24:179-191.
92. Schiffelers R.M., Bakker-Woudenberg I.A.J.M., Snijders S.V., Storm G. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochim. Biophys. Acta 1999, 1421:329-339.
93. Schiffelers R.M., Storm G., Bakker-Woudenberg I.A.J.M. Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. Int. J. Pharm. 2001, 19:103-105.
94. Schiffelers R.M., Storm G., Bakker-Woudenberg I.A.J.M. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm. Res. 2001, 18:780-787.
95. Schiffelers R., Storm G., ten Kate M.T., Stearne-Cullen L.E.T., Den Hollander J.G., Verbrugh H.A., Bakker-Woudenberg I.A.J.M. In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime. J. Pharmacol. Exp. Ther. 2001, 298:369-375.
96. Schiffelers R., Storm G., Bakker-Woudenberg I.A.J.M. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 2001, 48:333-344.
97. Sesin G.P., Manzi S.F., Pacheco R. New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection. Am. J. Health Syst. Pharm. 1996, 53:2585-2590.
98. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997, 154:123-140.
99. Sihorkar V., Vyas S.P. Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies. Pharm. Res. 2001, 18:1247-1254.
100. Storm G., Crommelin D.J.A. Liposomes: quo vadis?. Pharm. Sci. Technol. 1998, 1:19-31.
101. Swenson C.E., Popescu M.C., Ginsberg R.S. Preparation and use of liposomes in the treatment of microbial infections. Crit. Rev. Microbiol. 1988, 15:S1-31.
102. Trafny E.A., Stepińska M., Antos M., Grzybowski J. Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I. Antimicrob. Agents Chemother. 1995, 39:2645-2649.
103. Ulrich A.S. Biophysical aspects of using liposomes as delivery vehicles. Biosci. Rep. 2002, 22:129-150.
104. Vitas A.I., Diaz R., Gamazo C. Protective effect of liposomal gentamicin against systemic acute murine brucellosis. Chemotherapy 1997, 43:204-210.
105. Voinea M., Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J. Cell. Mol. Med. 2002, 6:465-474.
106. Vyas S.P., Sihorkar V., Mishra V. Controlled and targeted drug delivery strategies toward intraperiodontal pocket diseases: an overview. J. Clin. Pharm. Ther. 2000, 25:21-42.
107. Vyas S.P., Sihorkar V., Dubey P.K. Preparation, characterization and in vitro anti-microbial activity of metronidazole bearing lectinized liposomes for intra-periodontal pocket delivery. Pharmazie 2001, 56:554-560.
108. Webb M.S., Boman N.L., Wiseman D.J., Saxon D., Sutton K., Wong K.F., Logan P., Hope M.J. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob. Agents Chemother. 1998, 42:45-52.
109. Whitehead T.C., Lovering A.M., Cropley I.M., Wade P., Davidson R.N. Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 1998, 17:794-797.
110. Wiley E.L., Perry A., Nightingale S.D., Lawrence J. Detection of Mycobacterium avium-Mycobacterium intracellulare complex in bone marrow specimens of patients with acquired immunodeficiency syndrome. Am. J. Clin. Pathol. 1994, 101:446-451.
111. Wong J.P., Yang H., Blasetti K.L., Schnell G., Conley J., Schofield L.N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 2003, 92:265-273.
112. ®) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Antimicrob. Agents Chemother. 1999, 43:1737-1742.
113. Yang Y., Bhachech N., Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J. Antimicrob. Chemother. 1995, 35:75-84.
114. Yimei J., Joly H., Omri A. Liposomes as a carrier for gentamicin delivery: development and evaluation of the physicochemical properties. Int. J. Pharm. 2008, 359:254-263.
115. Yokouchi Y., Tsunoda T., Imura T., Yamauchi H., Yokoyama S., Sakai H., Abe M. Effect of adsorption of bovine serum albumin on liposomal membrane characteristics. Colloid Surf. B 2001, 20:95-103.
116. Zuidam N.J., Lee S.S., Crommelin D.J. Sterilization of liposomes by heat treatment. Pharm. Res. 1993, 10:1591-1596.